Turing Pharmaceuticals

See the following -

A Law Professor’s Big Idea for Combating Greedy Drug Company Titans Like Martin Shkreli

Noah Berlatsky | Quartz | September 21, 2017

In 2015, CEO of Turing Pharmaceuticals Martin Shkreli infamously raised the price of the life-saving drug Daraprim by 5,000%. Daraprim, developed more than 60 years ago, is used to treat the deadly parasitic infection toxoplasmosis. It was selling for $13.50 a pill; then Turing raised the price to $750. The move sparked massive backlash and Congressional hearings, and Shkreli himself was eventually arrested for, and convicted of, unrelated securities fraud charges. But the original, horrible problem didn’t get fixed. Turing kept the price sky-high; as of August 2016, many patients were paying $375 per pill...

Read More »

Australian High School Students Use Open Source to Make Shkreli's $750 Drug For Less Than $2

Press Release | University of Sydney | November 30, 2016

Sydney Grammar students, under the supervision of the University of Sydney and global members of the Open Source Malaria consortium, have reproduced an essential medicine in their high school laboratories. The drug, Daraprim, had been the subject of controversy when the price was hiked from US$13.50 to US$750 a dose last year. Daraprim - originally used as an antimalarial after its synthesis by Nobel Prize winner Gertrude Elion - is now more widely used as an anti-parasitic treatment for toxoplasmosis, which can be a dangerous disease for pregnant women and people with compromised immune systems, such as those living with HIV or AIDS...

Read More »

Australian Students Recreate Martin Shkreli Price-Hike Drug in School lab

Play VideoPlay Current Time 0:00 / Duration Time 0:49 Loaded: 0% Progress: 0% FullscreenMute Sydney students recreate life-saving drug that had 5,000% price hike Melissa Davey | The Guardian | November 30, 2016

A group of Australian high school students have managed to recreate a life-saving drug that rose from US$13.50 to US$750 a tablet overnight after an unscrupulous price-hike by former hedge fund manager Martin Shkreli. The Sydney Grammar students reproduced the drug, Daraprim, used to treat a rare but deadly parasitic infection, in their high school laboratory with support from the University of Sydney and global members of the Open Source Malaria consortium...

Read More »

Breaking Good: School Students Make Costly Drug Cheaply Using Open Source Approach

Press Release | University of Sydney | November 30, 2016

Sydney Grammar students, under the supervision of the University of Sydney and global members of the Open Source Malaria consortium, have reproduced an essential medicine in their high school laboratories. The drug, Daraprim, had been the subject of controversy when the price was hiked from US $13.50 to US$750 a dose last year. Daraprim - originally used as an antimalarial after its synthesis by Nobel Prize winner Gertrude Elion - is now more widely used as an anti-parasitic treatment for toxoplasmosis, which can be a dangerous disease for pregnant women and people with compromised immune systems, such as those living with HIV or AIDS...

Read More »

Martin Shkreli Congratulates Australian Students for Recreating Life-Saving Drug

Staff Writer | Fortune | December 2, 2016

Former pharmaceutical executive Martin Shkreli has congratulated a group of Australian students who reproduced the active ingredient for a life-saving, anti-parasitic drug at the centre of a drug-price controversy involving his former company. The students from Sydney Grammar School drew global media attention this week after they said they had produced the drug Daraprim for about $2 a dose, a fraction of the current list price of $750 per dose. Shkreli is a former chief executive of Turing Pharmaceuticals, where he sparked outrage among patients and U.S. lawmakers for raising the price of Daraprim by more than 5,000%...

Read More »

Mylan Isn't Alone: 11 Drugmakers with Off-the-Charts Pricing Power

Matt Krantz | USA Today | August 25, 2016

Mylan (MYL) is drawing fire for passing off massive price hikes for its EpiPen allergy treatment. But it’s far from being the drug company with the most pricing power. Gilead (GILD), Biogen (BIIB) and Amgen (AMGN), along with eight other drug giants in the Standard & Poor's 500, enjoyed off-the-charts pricing power on their products relative to costs — far beyond Mylan's, according to a USA TODAY analysis of data from S&P Global Market Intelligence...

Read More »

Open Source Malaria Helps Students with Proof of Concept Toxoplasmosis Pill

Paul Mutter | Geek Time | December 3, 2016

A team of Australian student researchers at Sydney Grammar School has managed to recreate the formula for Daraprim, the drug made (in)famous by the actions of Turing Pharmaceuticals last year when it increased the price substantially per pill. According to Futurism, the undertaking was helped along by an, “online research-sharing platform called Open Source Malaria [OSM], which aims to use publicly available drugs and medical techniques to treat malaria”...

Read More »